Zymeworks, a biotech company focused on cancer treatments, announced Monday that it will acquire Theravance Biopharma for $929 million in cash. The deal marks a significant strategic shift for Zymeworks, which is best known for its oncology pipeline, as it moves into respiratory medicine with the COPD drug Yupelri.
Yupelri (revefenacin) is already approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), a progressive lung condition that makes breathing difficult. The drug generated $266.6 million in U.S. net sales in 2025, a 12% increase from the prior year, and sales continued to grow 7% year-over-year to $62.4 million in the first quarter of 2026.
Under the terms of the deal, Zymeworks will receive a 35% share of Yupelri's U.S. net profits. The acquisition is expected to close in the second half of 2026, pending regulatory and shareholder approvals.
Why Zymeworks Is Buying Theravance
For a smaller biotech like Zymeworks, the appeal of Yupelri is straightforward: it is an already-approved, revenue-generating drug in a large and growing market. COPD affects millions of people worldwide, and the market is dominated by pharmaceutical giants such as GlaxoSmithKline (GSK), AstraZeneca, and Boehringer Ingelheim. By acquiring Theravance, Zymeworks gains immediate access to a commercial-stage product with a steady revenue stream, rather than relying solely on its own pipeline of experimental cancer therapies, which are years away from potential approval.
Theravance, for its part, had been exploring strategic alternatives after its rare-disease candidate ampreloxetine failed a late-stage clinical trial. That setback left the company without a clear path forward for its pipeline, making a sale a logical next step. Zymeworks has indicated it may still try to monetize ampreloxetine, with any future proceeds split 20% to Zymeworks and 80% to Theravance shareholders.
Market Reaction: Skepticism and a Drop
Despite the strategic logic, the market did not greet the deal with enthusiasm. Zymeworks shares fell more than 8% following the announcement, suggesting investors are questioning whether $929 million is a fair price for a 35% slice of Yupelri's U.S. profits, especially when sales growth is steady but not explosive. The COPD market is crowded with well-funded competitors, and integrating a respiratory drug into an oncology-focused company carries execution risks.
For Theravance shareholders, the deal offers a clear exit at $17 per share in cash. However, because the transaction is not expected to close until the second half of 2026, Theravance's stock is likely to trade near that price, with any gap representing the market's assessment of the risk of delays or a broken deal. In effect, Theravance shares become a deal stub, while Zymeworks becomes the pressure valve for changing views on the deal's value.
What It Means for Investors
All-cash acquisitions like this one often turn the target company's stock into a time-and-risk trade. Theravance investors who hold through to closing will receive $17 per share, but they must wait more than a year for that payout. Any discount to $17 reflects the market's implied cost of waiting and the possibility that the deal could fall through.
For Zymeworks investors, the calculus is different. The company is taking on debt or using cash reserves to fund the acquisition, and the market's negative reaction suggests some doubt about whether Yupelri's steady but modest growth justifies the price tag. Zymeworks will need to demonstrate that it can manage the integration and compete effectively in a market dominated by deep-pocketed incumbents.
Meanwhile, the broader biotech sector has seen a wave of M&A activity as larger companies seek to bolster their pipelines and smaller firms look for exits. This deal fits that pattern, but the long timeline to closing means investors will have to wait to see if the promised near-term cash flow materializes.
For everyday investors, the key takeaway is that this acquisition is a bet on Yupelri's continued sales growth and Zymeworks' ability to execute in a new therapeutic area. The market's skepticism is a reminder that even well-structured deals can face headwinds, especially when they involve moving into unfamiliar territory.
